EVALUTE THE EFFICACY OF ADJUVANT REGIMEN 3FEC- 3T IN STAGE II BREAST CANCER Hai Phong, 2017 LÊ THU HÀ, Ph.D. Nguyễn Khánh Hà, Dr.

Introduction Breast cancer is the most commonly diagnosed cancer in women Global (2012): 1,6 million new cases. Viet Nam (2010): 18.424 new cases. Rate of women diagnosed at the early stage (I, II) increases, mortality rate decreases. Adjuvant chemotherapy, hormone therapy, target therapy are the common ways to treat breast cancer after mastectomy.

Introduction Adjuvant chemotherapy can lower the risk cancer coming back and prolong survival Regimens in the clinical : AC , CAF , CMF , 4AC – 4T TAC, 3FEC – 3T, 4AC , TC… Sequencial adjuvant 3FEC – 3T was demonstrated efficacy in breast cancer on the World. Ha Noi Oncology Hospital started perform 3FEC – 3T in 2010.

OBJECTIVE This study is aim to evaluate the efficacy and the toxicity of 3FEC – 3T regimen in breast cancer patients with stage II after mastectomy.

OVERVIEW Diagnosis Stage TNM Multidemensional treatment Adjuvant chemotherapy Clinical trials

PATIENTS AND METHOD Patients: Restrospective study of 65 stage II breast cancer patients underwent mastectomy given 3FEC – 3T regimen from 10/2010 to 31/12/2014 at Ha Noi Oncology Hospital.

PATIENTS AND METHOD Method: Clinical presentation Staging TNM Surgery Mortality and morbidity Toxicity of regimen

RESULT AND DISCUSSION Age Mean age : 49.8 ±7.926, min: 28, max: 67

RESULT AND DISCUSSION Tumor distance

Kết quả và bàn luận Đặc điểm về di căn hạch

RESULT AND DISCUSSION Pathology

RESULT AND DISCUSSION Her2-neu Her-2 Number of patient Rate (%) Negative 37 56,93 Positive 28 43,07 Total 65 100 

RESULT AND DISCUSSION Hormone receptor Feature No. patient Rate (%) ER   Negative 25 38,46 Positive 40 61,54 PR 32 49,23 33 50,77 Total 65 100

Time to Median follow – up time : 42,75 ± 13,95 months Max : 78 months Min : 25 months

DFS DFS 3 years: 78,8% DFS 5 years: 75,6%

OS OS 3 years: 96,8% OS 5 years: 94,2%

RESULT AND DISCUSSION Clinical Trials PAC-01 GEICAM 9906 TACT We Roche’ H et al (2006) Miguel Martín et al (2008) Ellis P et al (2009) Clinical Trials PAC-01 GEICAM 9906 TACT We DFS (5 năm) 78.4% 78.5% 74,3% 75.6% OS (5 năm) 90.7% - 94.2%

RESULT AND DISCUSSION Phác đồ FAC CMF 3FEC-3T DFS (5 năm) 70.97% Nguyễn Bá Đức, Trần Văn Thuấn (2002) Trần Văn Thuấn và cs (2005) Nguyễn Thị Sang, Trần Thắng, Trần Văn Thuấn, Vũ Hồng Thăng (2014) Phác đồ FAC CMF 3FEC-3T DFS (5 năm) 70.97% 66.67% 75.6% OS (5 năm) 80.65% 76.67% 94.2%

Correlative between DFS and N

Correlative between DFS and HR

DFS and other factors DFS và Her2/neu DFS và T

RESULT AND DISCUSSION Hematology toxicity

Toxicity

Toxicity

Toxicity Level 1 No. (%) Level 2 Level 3 Level 4 Chán ăn 40 (61,5)   Level 1 No. (%) Level 2 Level 3 Level 4 Chán ăn 40 (61,5) 5 (7,7) Anoresia 50 (76,9) 15 (23,1) Ure/ Creatinin Cardiology Neurosensory 27 (41,5) 10 (15,4)

Conclusion DFS and OS improved . DFS after 3 year and 5 year are 78,8%; 75,6% respectivly and OS after 3 year and 5 year are 96,8%; 94,2%. N (+) lead to decrease survival. DFS and N (+) is 84,7%, DFS and N (-) is 64,7% DFS and HR (+) is higher than DFS and HR (-) (83,8% và 67,7%)

THANKS FOR YOUR ATTENTION